• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is Paxil the Best SSRI for Anxiety?

Is Paxil the Best SSRI for Anxiety?

August 30, 2019
Chris Aiken, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris Aiken, MD Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dear Dr. Aiken: Your review of Paxil’s risks in the May issue failed to mention a benefit that’s unique to this drug. Isn’t it the best SSRI for anxiety?

Dr. Aiken: Paroxetine’s (Paxil’s) reputation as the anti-anxiety SSRI got off to a running start. It was first launched for panic disorder in 1996, two years before its approval for depression, and went on to gain approval in 4 other anxiety disorders. A rumor began to percolate that paroxetine was a better choice for anxious patients, and it continues to be spread. For example, Stephen Stahl highlights it on his website: “In clinical practice, many clinicians use [paroxetine] for patients with anxious depression.”

The data tells a different story. In head-to-head comparisons, paroxetine works as well as other serotonergic agents in anxiety disorders, and sometimes worse. That includes around a dozen large, head-to-head trials in generalized anxiety disorder, social anxiety disorder, panic disorder, and major depression with anxiety. It fared no better than sertraline, citalopram, venlafaxine, and clomipramine, and was consistently outperformed by escitalopram (Sanchez C et al, Int Clin Psychopharmacol 2014;29:185-196). Overall, paroxetine has only modest anxiolytic effects (effect size of 0.3), and anxiety does not predict whether a depressed patient will respond to it (Sugarman MA et al, PLoS One 2014;27(9):e106337).

Paroxetine does hold more FDA-approvals in anxiety disorders than most other antidepressants: panic disorder, generalized anxiety disorder, social anxiety disorder, PTSD, and OCD. Those approvals came with a license to market, and that marketing may be responsible for its clinical lore. Side effects may have also assisted in its reputation. Paroxetine causes more fatigue than other SSRIs, and sedative effects can be conflated with anxiolytic effects (Nevels RM et al, Psychopharmacol Bull 2016;46:77-104).

Paroxetine does stand out in a few ways that aren’t so desirable. It has higher rates of weight gain, sexual dysfunction, withdrawal problems, anticholinergic effects, congenital malformations, and CYP2D6 drug interactions than other SSRIs (Marks DM et al, Expert Opin Drug Saf 2008;7:783-794). Our May 2019 issue added another risk to that list: dementia. There may be patients who respond uniquely to paroxetine, but anxiety is not a reliable guide to finding them.
General Psychiatry
KEYWORDS antidepressants anxiety anxiety disorders generalized-anxiety-disorder panic-disorder pharmaceutical_industry pharmacology pharmacology-tips practice_tools_and_tips psychopharm-myths psychopharmacology psychopharmacology_tips ptsd social-anxiety-disorder ssris
    Aiken eic 150x150
    Chris Aiken, MD

    Ketamine Assisted Therapy Part I

    More from this author
    www.thecarlatreport.com
    Issue Date: August 30, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - How to Talk about Medication, TCPR, September 2019
    Is There a Case for Cannabis in the Treatment of Pain?
    Is Paxil the Best SSRI for Anxiety?
    A New Contraindication for Ambien and the Z-Hypnotics
    A New Way to Talk to Patients about Medication
    Mirtazapine Augmentation: Running Low on Rocket Fuel
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.